샘플 요청 목록

 카트 문의
시장보고서
상품코드
1937081

갱년기 안면 홍조 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

Global Menopausal Hot Flashes Market Size, Share, Trends & Growth Analysis Report 2026-2034
발행일: | 리서치사: Value Market Research | 페이지 정보: 영문 113 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

갱년기 안면 홍조 시장 규모는 2025년 97억 9,000만 달러에서 2026년부터 2034년까지 CAGR 6.52%로 성장하여 2034년에는 172억 8,000만 달러에 달할 것으로 예측됩니다.

갱년기 관련 안면 홍조 시장은 여성의 갱년기 관련 증상에 대한 인식과 진단이 증가함에 따라 큰 폭의 성장이 예상됩니다. 전 세계적으로 고령화에 따라 안면 홍조를 포함한 갱년기 증상의 유병률이 증가하고 있어 효과적인 치료법의 필요성이 높아지고 있습니다. 호르몬 대체요법(HRT)이나 비호르몬 요법 등 대체요법이 증상 관리와 삶의 질 향상을 원하는 여성들에게 주목받고 있습니다. 새로운 치료법과 치료 양식에 대한 지속적인 연구는 시장을 더욱 확대하고 여성의 불편함을 완화할 수 있는 선택지를 늘려줄 것으로 기대됩니다.

또한, 맞춤형 의료에 대한 관심이 높아진 것도 갱년기 증상 시장에 긍정적인 영향을 미치고 있습니다. 환자 개개인의 특성을 고려한 맞춤형 치료 접근법이 보급되어 효과와 안전성이 향상되고 있습니다. 첨단 진단 도구와 환자 교육을 치료 프로토콜에 통합함으로써 의료진은 보다 정밀한 개입을 할 수 있게 되었습니다. 맞춤형 치료의 가능성을 조사하는 연구가 계속되면서 시장은 확대될 것으로 예상되며, 제조업체와 의료 서비스 제공자 모두에게 새로운 기회를 제공할 것으로 보입니다.

또한, 여성 건강 문제와 예방 의료에 대한 인식이 높아지면서 시장 성장에 크게 기여할 것으로 예상됩니다. 갱년기와 그 관리에 대한 인식 개선 활동이 주목받고 있으며, 치료 옵션에 대한 수요 증가로 이어지고 있습니다. 여성들이 자신의 건강에 더 적극적으로 참여하고 효과적인 관리 전략을 추구함에 따라 갱년기 안면 홍조 치료 시장은 수요가 급증하고 향후 몇 년 동안 견조한 성장세를 보일 것으로 예상됩니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 변수, 동향, 프레임워크

제4장 세계의 갱년기 안면 홍조 시장 : 치료 유형별

제5장 세계의 갱년기 안면 홍조 시장 : 유통 채널별

제6장 세계의 갱년기 안면 홍조 시장 : 지역별

제7장 경쟁 구도

제8장 기업 개요

KSM 26.03.11

The Menopausal Hot Flashes Market size is expected to reach USD 17.28 Billion in 2034 from USD 9.79 Billion (2025) growing at a CAGR of 6.52% during 2026-2034.

The menopausal hot flashes market is poised for significant growth, driven by the increasing awareness and diagnosis of menopause-related symptoms among women. As the global population ages, the prevalence of menopausal symptoms, including hot flashes, is rising, necessitating effective treatment options. Hormone replacement therapy (HRT) and non-hormonal alternatives are gaining traction as women seek to manage their symptoms and improve their quality of life. The ongoing research into novel therapies and treatment modalities is likely to further enhance the market, providing women with more options for alleviating their discomfort.

Moreover, the growing emphasis on personalized medicine is influencing the menopausal hot flashes market positively. Tailored treatment approaches that consider individual patient characteristics are becoming more prevalent, leading to improved efficacy and safety profiles. The integration of advanced diagnostic tools and patient education into treatment protocols is enabling healthcare professionals to deliver more precise interventions. As research continues to explore the potential of personalized therapies, the market is expected to expand, offering new opportunities for manufacturers and healthcare providers alike.

Additionally, the rising awareness of women's health issues and preventive care is anticipated to contribute significantly to market growth. Educational initiatives aimed at promoting awareness of menopause and its management are gaining traction, leading to increased demand for treatment options. As women become more proactive about their health and seek effective management strategies, the market for menopausal hot flash treatments is likely to witness a surge in demand, positioning it for robust growth in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Treatment Type

  • Hormonal Treatment (Estrogen, Progesterone, Estrogen-Progesterone Combination)
  • Non-hormonal Treatment (Antidepressant, Gabapentin, Pregabalin, Clonidine)
  • Alternative Treatment (Black Cohosh, Vitamin E, Herbal Medicines, Others)

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

COMPANIES PROFILED

  • Pfizer Inc, Novartis AG, Novo Nordisk AS, Allergan plc, Teva Pharmaceutical Industries Ltd, Mylan NV, Hisamitsu Pharmaceutical Co Inc, Merck Co Inc, GlaxoSmithKline pic, TherapeuticsMD Inc

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL MENOPAUSAL HOT FLASHES MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Treatment Type
  • 4.2. Hormonal Treatment (Estrogen, Progesterone, Estrogen-Progesterone Combination) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Non-hormonal Treatment (Antidepressant, Gabapentin, Pregabalin, Clonidine) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Alternative Treatment (Black Cohosh, Vitamin E, Herbal Medicines, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MENOPAUSAL HOT FLASHES MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Distribution Channel
  • 5.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MENOPAUSAL HOT FLASHES MARKET: BY REGION 2022-2034(USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Treatment Type
    • 6.2.2 By Distribution Channel
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Treatment Type
    • 6.3.2 By Distribution Channel
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Treatment Type
    • 6.4.2 By Distribution Channel
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Treatment Type
    • 6.5.2 By Distribution Channel
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Treatment Type
    • 6.6.2 By Distribution Channel
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL MENOPAUSAL HOT FLASHES INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 Pfizer Inc
    • 8.2.2 Novartis AG
    • 8.2.3 Novo Nordisk A/S
    • 8.2.4 Allergan Plc
    • 8.2.5 Teva Pharmaceutical Industries Ltd
    • 8.2.6 Mylan NV
    • 8.2.7 Hisamitsu Pharmaceutical Co. Inc
    • 8.2.8 Merck & Co. Inc
    • 8.2.9 GlaxoSmithKline Pic
    • 8.2.10 TherapeuticsMD Inc
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제